Ludger Klimek, Ulrike Förster-Ruhrmann, Achim G. Beule, Adam M. Chaker, Jan Hagemann, Felix Klimek, Ingrid Casper, Tilman Huppertz, Thomas K. Hoffmann, Stefan Dazert, Thomas Deitmer, Heidi Olze, Sebastian Strieth, Holger Wrede, Wolfgang Schlenter, Hans-Jürgen Welkoborsky, Barbara Wollenberg, Christoph Bergmann, Mandy Cuevas, Caroline Beutner, Moritz Gröger, Sven Becker
{"title":"慢性鼻窦炎伴鼻息肉的指示性生物制剂（CRSwNP）","authors":"Ludger Klimek, Ulrike Förster-Ruhrmann, Achim G. Beule, Adam M. Chaker, Jan Hagemann, Felix Klimek, Ingrid Casper, Tilman Huppertz, Thomas K. Hoffmann, Stefan Dazert, Thomas Deitmer, Heidi Olze, Sebastian Strieth, Holger Wrede, Wolfgang Schlenter, Hans-Jürgen Welkoborsky, Barbara Wollenberg, Christoph Bergmann, Mandy Cuevas, Caroline Beutner, Moritz Gröger, Sven Becker","doi":"10.1007/s40629-022-00220-x","DOIUrl":null,"url":null,"abstract":"<div><h2>Summary</h2><div><h3>Background</h3><p>Chronic rhinosinusitis with nasal polyps (CRSwNP), an inflammatory disease of the paranasal mucosa, is primarily characterized by type 2 inflammation. Three antibodies (dupilumab, omalizumab, and mepolizumab) are now approved for the treatment of severe CRSwNP. Documentation of disease severity during the course of treatment is essential.</p><h3>Methods</h3><p>A literature search of Medline, PubMed, and the national and international trial and guideline register, and the Cochrane Library was performed to analyze the immunology of CRSwNP and determine the evidence for the effect of dupilumab, omalizumab, and mepolizumab in this disease. This has resulted in 3 position papers prepared by our group of authors, which form the basis of this summarizing review.</p><h3>Results</h3><p>Based on the information from the international literature, recommendations for the use of dupilumab, omalizumab, and mepolizumab in CRSwNP in the German health care system are given by an expert panel.</p><h3>Conclusion</h3><p>Dupilumab, omalizumab, and mepolizumab are approved for patients 18 years of age and older with CRSwNP as add-on therapy to intranasal corticosteroids when, for dupilumab and mepolizumab, therapy with systemic corticosteroids and/or surgery does not achieve sufficient disease control. Therapy with omalizumab is indicated when therapy with intranasal corticosteroids does not result in sufficient disease control. Dedicated recommendations for the documentation of the use in the German health care system are given, which are based on the position papers of our author group already published on this topic.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 6","pages":"149 - 160"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00220-x.pdf","citationCount":"3","resultStr":"{\"title\":\"Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)\",\"authors\":\"Ludger Klimek, Ulrike Förster-Ruhrmann, Achim G. Beule, Adam M. Chaker, Jan Hagemann, Felix Klimek, Ingrid Casper, Tilman Huppertz, Thomas K. Hoffmann, Stefan Dazert, Thomas Deitmer, Heidi Olze, Sebastian Strieth, Holger Wrede, Wolfgang Schlenter, Hans-Jürgen Welkoborsky, Barbara Wollenberg, Christoph Bergmann, Mandy Cuevas, Caroline Beutner, Moritz Gröger, Sven Becker\",\"doi\":\"10.1007/s40629-022-00220-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h2>Summary</h2><div><h3>Background</h3><p>Chronic rhinosinusitis with nasal polyps (CRSwNP), an inflammatory disease of the paranasal mucosa, is primarily characterized by type 2 inflammation. Three antibodies (dupilumab, omalizumab, and mepolizumab) are now approved for the treatment of severe CRSwNP. Documentation of disease severity during the course of treatment is essential.</p><h3>Methods</h3><p>A literature search of Medline, PubMed, and the national and international trial and guideline register, and the Cochrane Library was performed to analyze the immunology of CRSwNP and determine the evidence for the effect of dupilumab, omalizumab, and mepolizumab in this disease. This has resulted in 3 position papers prepared by our group of authors, which form the basis of this summarizing review.</p><h3>Results</h3><p>Based on the information from the international literature, recommendations for the use of dupilumab, omalizumab, and mepolizumab in CRSwNP in the German health care system are given by an expert panel.</p><h3>Conclusion</h3><p>Dupilumab, omalizumab, and mepolizumab are approved for patients 18 years of age and older with CRSwNP as add-on therapy to intranasal corticosteroids when, for dupilumab and mepolizumab, therapy with systemic corticosteroids and/or surgery does not achieve sufficient disease control. Therapy with omalizumab is indicated when therapy with intranasal corticosteroids does not result in sufficient disease control. Dedicated recommendations for the documentation of the use in the German health care system are given, which are based on the position papers of our author group already published on this topic.</p></div></div>\",\"PeriodicalId\":37457,\"journal\":{\"name\":\"Allergo Journal International\",\"volume\":\"31 6\",\"pages\":\"149 - 160\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s40629-022-00220-x.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergo Journal International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s40629-022-00220-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergo Journal International","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s40629-022-00220-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)
Summary
Background
Chronic rhinosinusitis with nasal polyps (CRSwNP), an inflammatory disease of the paranasal mucosa, is primarily characterized by type 2 inflammation. Three antibodies (dupilumab, omalizumab, and mepolizumab) are now approved for the treatment of severe CRSwNP. Documentation of disease severity during the course of treatment is essential.
Methods
A literature search of Medline, PubMed, and the national and international trial and guideline register, and the Cochrane Library was performed to analyze the immunology of CRSwNP and determine the evidence for the effect of dupilumab, omalizumab, and mepolizumab in this disease. This has resulted in 3 position papers prepared by our group of authors, which form the basis of this summarizing review.
Results
Based on the information from the international literature, recommendations for the use of dupilumab, omalizumab, and mepolizumab in CRSwNP in the German health care system are given by an expert panel.
Conclusion
Dupilumab, omalizumab, and mepolizumab are approved for patients 18 years of age and older with CRSwNP as add-on therapy to intranasal corticosteroids when, for dupilumab and mepolizumab, therapy with systemic corticosteroids and/or surgery does not achieve sufficient disease control. Therapy with omalizumab is indicated when therapy with intranasal corticosteroids does not result in sufficient disease control. Dedicated recommendations for the documentation of the use in the German health care system are given, which are based on the position papers of our author group already published on this topic.
期刊介绍：
Allergo Journal International is the official Journal of the German Society for Applied Allergology (AeDA) and the Austrian Society for Allergology and Immunology (ÖGAI). The journal is a forum for the communication and exchange of ideas concerning the various aspects of allergy (including related fields such as clinical immunology and environmental medicine) and promotes German allergy research in an international context. The aim of Allergo Journal International is to provide state of the art information for all medical and scientific disciplines that deal with allergic, immunological and environmental diseases. Allergo Journal International publishes original articles, reviews, short communications, case reports, and letters to the editor. The articles cover topics such as allergic, immunological and environmental diseases, the latest developments in diagnosis and therapy as well as current research work concerning antigens and allergens and aspects related to occupational and environmental medicine. In addition, it publishes clinical guidelines and position papers approved by expert panels of the German, Austrian and Swiss Allergy Societies.
All submissions are reviewed in single-blind fashion by at least two reviewers.
Originally, the journal started as a German journal called Allergo Journal back in 1992. Throughout the years, English articles amounted to a considerable portion in Allergo Journal. This was one of the reasons to extract the scientific content and publish it in a separate journal. Hence, Allergo Journal International was born and now is the international continuation of the original German journal. Nowadays, all original content is published in Allergo Journal International first. Later, selected manuscripts will be translated and published in German and included in Allergo Journal.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
